TL;DR
AI in pharmacovigilance speeds up the high-volume parts of drug safety work, such as case intake, literature screening, coding suggestions, duplicate checks and signal ranking. People keep the decisions that carry regulatory and clinical weight. Those include case validity, seriousness, causality, case merges and submission sign-off. Regulators have issued principles rather than an AI rulebook, and FDA’s AI guidance is still a draft as of November 2026. Safe deployment means validating each tool for its intended use and keeping an audit trail of every suggestion and edit. Start with one bounded task, measure missed events first, and scale only when the evidence holds.
Key Takeaways AI in pharmacovigilance works best on high-volume, checkable tasks such as intake, extraction, literature triage, coding suggestions and duplicate detection. A detected adverse event mention is not a valid case until the four minimum criteria are met and a person confirms it. Rules, NLP models, generative AI and agents suit different safety tasks, so start with the simplest tool that does the job. Regulators offer principles, not an AI rulebook, because FDA’s AI guidance is still a draft and the FDA-EMA principles and CIOMS XIV report are non-binding. Validate against an adjudicated test set, track missed events first, and revalidate when models, prompts or MedDRA versions change. Measure value as accepted, compliant output per reviewer hour, not model accuracy alone. Watch on YouTube
Can AI Transform Healthcare: Trends and Technologies to Watch
A Kanerika look at the AI trends and technologies to watch in healthcare, wider context for the drug safety use cases this guide narrows down.
Finding One Safety Signal in Forty Million Reports
VigiBase, the WHO global database of suspected adverse reactions, held more than 40 million reports from over 180 WHO programme members as of February 2025. Somewhere in that pile, though, a small number of reports may describe a real, unknown risk from a medicine. The rest is noise that still has to be read, coded and filed.
The noise is not tidy either. FDA warns that its own database, AEMS (formerly FAERS) , contains duplicate and incomplete reports. It also reminds readers that a report about a drug does not mean the drug caused the event.
Meanwhile, the clock runs. Once a serious, unexpected case reaches a US applicant, it must be reported within 15 calendar days of first receipt. That pressure is why safety leaders keep asking which tasks AI can take over, under which controls, and with whose sign-off.
What Is AI in Pharmacovigilance?
AI in pharmacovigilance is the use of rules engines, natural language processing, machine learning, generative models and agents to support drug safety work. WHO defines pharmacovigilance as the science and activities relating to the detection, assessment, understanding and prevention of adverse effects and other medicine-related problems. AI can help with each of those activities, but the marketing authorization holder stays accountable for the outcome.
This guide covers post-approval safety operations. AI for discovery and clinical trials is a different subject, so it is covered separately on Kanerika’s AI in pharma page.
Where AI Fits in the Drug Safety Workflow
A safety case moves through five broad steps. First, intake captures the report from an email, a form, a call note or a journal abstract. A validity check then confirms the four minimum criteria, and coding maps the reported terms to MedDRA.
After that comes medical review, where a qualified person judges seriousness, expectedness and causality. Finally, the case is submitted with human sign-off, and it joins the data that signal management reviews over time. AI assists at every step, while people make the decisions.
Why Traditional Case Processing Strains Under Volume
Manual case processing was built for a smaller and cleaner inflow than the one safety teams handle. Duplicates arrive when a patient, a doctor and a partner company all report the same event. Incomplete reports need follow-up before anyone can decide whether they qualify as cases.
At the same time, the sources keep widening. The revised ICH guideline, ICH E2D(R1) , adds guidance for digital platforms, social media, mobile health, patient support programmes, market research and literature. Each of those channels produces unstructured text that someone has to read before a deadline.
The reporting format has also become more demanding. Under E2B(R3), FDA notes that seriousness is assessed at the event level rather than the case level , and attachments are embedded in the report. Extraction therefore has to capture seriousness for each event, not once per case.
Rules, NLP, Generative AI and Agents Are Different Tools
“AI” covers several technologies with very different risk profiles, so it helps to separate four families. Rules and workflow automation handle fixed logic, such as routing or flagging a missing reporter field, although they break when source formats change. NLP and machine learning models classify and extract text at scale, but they can miss events or misread negations.
Generative AI writes summaries, drafts and translations, such as a first case narrative. However, it can also produce unsupported statements that read as fact. Finally, AI agents carry out multi-step tasks across systems, like gathering follow-up items, and they need tight limits once they get write access.
The simplest family that meets the task is also easier to validate, because a rule that checks for a missing field never invents one. Tools built on natural language processing sit in the middle, and they suit intake work since the output can be checked against the source.
AI in Pharmacovigilance Use Cases That Work in Practice
The use cases that hold up in practice share three traits. First, the task is high volume. A reviewer can also check the output against the source, and any error is visible before anything leaves the building. The CIOMS working group on AI in pharmacovigilance lists similar ground in its 2025 consultation draft , including data extraction, deduplication, translation and signal detection efficiencies.
Case Intake and Validity Checks
Intake is where volume hurts most. Models can read an inbound email or form and find a possible adverse event. Then they pull the reporter, patient, product and reaction details into a structured record.
Under EU GVP Module VI , a valid case needs four elements. Those are an identifiable reporter, an identifiable patient, at least one suspected medicinal product and at least one suspected adverse reaction. When any one is missing, the case is incomplete and does not qualify for submission.
AI is useful here as a checker rather than a judge. For instance, it can flag which of the four elements it found, where it found them, and which ones need follow-up. A person then confirms validity. That split matters because the same module sets deadlines. Serious valid cases are due within 15 days and non-serious ones within 90, both counted from receipt.
Literature, Social and Digital-Source Screening
Safety teams also screen medical literature for case reports involving their products. A model can rank abstracts by how likely they are to contain a reportable case, so reviewers read the strongest candidates first. Social media and patient support channels work the same way, although the text is messier and the reporter is often harder to identify.
Still, the control is simple to state. Anything the model scores as irrelevant still needs a sampled human check, because a missed case costs far more than a wasted read. Kanerika’s guide to intelligent document processing explains how this kind of document triage is built for regulated content.
MedDRA Coding Suggestions and Duplicate Detection
MedDRA has five levels, from System Organ Class down to the most specific Lowest Level Terms. Coders pick the term that best matches the reporter’s words, while a model can suggest the top candidates with the source phrase beside each one. The coder then accepts, edits or rejects each one, and every choice becomes training and audit evidence.
Duplicate detection is a natural fit for machine learning as well. A model can score how closely two reports match on patient age, sex, product, event and dates, then send likely pairs to a reviewer. Merging stays a human action, since a wrong merge can erase a real second case.
Narrative Drafting From Source Documents
Case narratives take time to write, even though they follow a familiar pattern. Because of that pattern, a generative model can draft one from the structured fields and attached source documents. That draft is where hallucination risk is highest, so every sentence needs a traceable source and a reviewer who reads against it.
In practice, a useful control is a target for the share of narrative statements with no support in the source. Kanerika’s generative AI services page covers the wider build around models like these. The source check is the safety feature, because a fluent draft proves nothing on its own.
Checklist
Generative AI Checklist
A practical checklist for secure generative AI adoption, covering data handling, access controls and governance before a model drafts anything that reaches a regulated record.
Get the Checklist → Signal Detection and Prioritization
EMA describes a safety signal as information on a new or known adverse event that may be caused by a medicine and requires further investigation . Classic disproportionality methods check whether an event appears more often with one product than with all others. Machine learning can add features such as case quality, time to onset or clustering across sources, which helps rank what to review first.
Ranking is not confirmation, though. A high score earns a closer look by the safety team, and the team still decides whether a signal is validated. The table also sums up where each use case adds value and where it can fail.
Workflow Suitable AI approach Potential value Main failure mode Human checkpoint Case intake NLP classification and extraction Faster triage of inbound reports Missed or misread events Validity confirmation Literature screening Relevance ranking Reviewers read likely cases first Relevant abstract ranked low Sampled check of low scores MedDRA coding Term suggestion Fewer manual lookups Plausible but wrong term Coder accepts or edits Duplicate detection Similarity scoring Cleaner case counts Wrong merge or missed pair Merge approval Narrative drafting Generative AI with source tracing Faster first drafts Unsupported statements Line-by-line source review Signal prioritization Disproportionality plus ML ranking Earlier attention to strong signals False alarms or buried signals Signal validation by safety team
What to Automate and What Must Stay Human
Every pharmacovigilance automation decision comes down to four questions. How much clinical impact does the task carry, and how easily can an error be reversed? Then ask how likely a reviewer is to notice it, and how good the model’s evidence is. Tasks that score low on impact and high on detectability can therefore move toward automation first.
Similarly, the CIOMS XIV work frames the idea through two oversight models. With a human in the loop, the decision comes from the interaction between a person and the machine. With a human on the loop, by contrast, the machine acts while a person monitors and checks it. CIOMS ties the choice between them to the risk of the task.
Tasks Suited to Controlled Automation
Routing inbound reports to the right queue is a good early candidate, since a misrouted email is caught at the next step. Literature triage also fits, provided low-scoring abstracts get a sampled human check. Format checks, translation drafts and deadline tracking also belong in the same group.
Controlled automation still means controls. Thresholds are set in advance, and a person reviews a sample of automated decisions. Anything the model is unsure about goes to a human queue instead of a default answer.
Decisions That Need Accountable Review
Some decisions carry regulatory and clinical weight, and they stay with qualified people. Validity, seriousness, expectedness, causality, case merges and submission sign-off all sit here. AI can prepare the evidence for each one, but it should not make the call.
Oversight only counts when it is real. In other words, a reviewer needs enough time per case, direct access to the source document and clear authority to override the model. Kanerika’s piece on human-in-the-loop design for AI agents covers how those review points are built into a workflow.
Regulations and Guidance Shaping AI in Pharmacovigilance (2026)
No regulator has published a rulebook written only for AI in drug safety. Instead, binding reporting rules sit alongside non-binding AI principles, and a safety team has to satisfy both. The status below was checked in November 2026.
US: Reporting Rules, E2B(R3) and FDA’s Draft AI Guidance
The binding rules are the same whether a person or a model processes the case. Under 21 CFR 314.80 , applicants must report each serious and unexpected adverse drug experience within 15 calendar days of initial receipt. 21 CFR 600.80 likewise sets the same timeline for biologics.
The postmarketing reporting format, on the other hand, changed in 2026. FDA states that beginning October 1, 2026, all ICSRs submitted via the ESG NextGen must use E2B(R3) data standards . FDA accepted E2B(R2) reports through September 30, 2026, after a six-month extension.
On AI itself, FDA’s guidance on using AI to support regulatory decision-making for drugs and biologics is still a January 2025 draft. In particular, it proposes a risk-based credibility assessment tied to the model’s context of use. FDA also runs the Emerging Drug Safety Technology Program , a forum for dialogue with industry on AI in pharmacovigilance. Regulators use AI as well. For example, FDA says AEMS is designed to use AI-based redaction and digitization tools.
EU and Global: GVP Module VI, EMA, ICH E2D(R1) and CIOMS XIV
In the EU, GVP Module VI (Rev 2) governs how suspected adverse reaction reports are collected, managed and submitted to EudraVigilance . ICH E2D(R1) also took effect in the EU on 18 March 2026, replacing the 2003 guideline.
EMA adopted a reflection paper on AI across the medicinal product lifecycle in September 2024. Later, on 14 January 2026, EMA and FDA jointly published ten guiding principles of good AI practice that cover safety monitoring. The most specific framework is the CIOMS Working Group XIV report , published on 4 December 2025. Its principle areas include a risk-based approach and human oversight, as well as validity, transparency, data privacy, fairness and governance.
Kanerika Service
AI Governance Consulting
Kanerika’s AI governance consulting covers the controls that decide how AI systems are built, deployed, monitored and held accountable, including exposure under GDPR and the EU AI Act.
Explore AI Governance Where the EU AI Act Fits
The EU AI Act does not label pharmacovigilance tools high-risk by default. Instead, classification depends on what a system does and where it sits. After the AI Omnibus, high-risk rules for Annex III use cases apply from 2 December 2027 . Rules for AI inside Annex I regulated products follow from 2 August 2028.
If a tool is classed as high-risk, Article 14 requires that people can oversee it effectively while it runs. It also asks that overseers stay aware of automation bias. Kanerika’s guide to EU AI Act compliance walks through the classification steps.
Instrument Type Status as of November 2026 What it means for AI 21 CFR 314.80 and 600.80 Binding rule (US) In force 15-day clock applies when AI processes the case 21 CFR Part 11 Binding rule (US) In force Electronic records need trustworthy controls E2B(R3) for US postmarketing ICSRs Data standard Required via ESG NextGen from 1 Oct 2026 Extraction must map to event-level fields before submission FDA AI guidance (Jan 2025) Draft guidance Draft, not final Credibility tied to context of use FDA-EMA ten AI principles Principles Published 14 Jan 2026 Non-binding expectations across the lifecycle EMA AI reflection paper Reflection paper Adopted Sep 2024 Risk-based use across the lifecycle GVP Module VI (Rev 2) EU guidance on legal timelines In force 15-day and 90-day timelines, four criteria ICH E2D(R1) ICH guideline EU effective 18 Mar 2026 More digital sources to screen CIOMS XIV report Consensus report Published 4 Dec 2025 PV-specific AI principles EU AI Act Binding regulation High-risk rules from Dec 2027 or Aug 2028 Applies only when a tool is classed high-risk
Build a Governed Architecture Around the Safety Database
The safety database stays the system of record. AI services sit around it, read from governed copies of the data, and then write back only through a reviewed path. That design keeps every regulated record where auditors expect it.
Keep Provenance From Source to Field
Every extracted field should point back to the exact place in the source where it came from. When a reviewer sees “patient age 64”, they should be able to click through to the sentence that said so. As a result, provenance turns review from re-reading into checking.
It also depends on clean, consistent data. Mapping reported terms, units and dates into one shared format is the subject of Kanerika’s guide to data standardization . Tracking where each value moved over time is data lineage , and auditors will ask for both.
Separate Ingestion, Inference, Review and Write-Back
A sound design keeps five layers apart. Sources feed a governed data layer through controlled ingestion. An AI service reads from that layer, sends its output to a review queue, and only approved changes reach the safety database.
Under 314.80(g) , safety reports must arrive in an electronic format FDA can process, review and archive. The write-back step must therefore produce clean E2B(R3) output rather than a model’s free text.
Around those layers sit the controls. Identity and access rules, encryption, access logs, model and prompt versions and a rollback plan belong in the design from day one. Residency and access policies across clouds are covered in the guide to cloud governance . Kanerika’s data governance services also cover the policy side of this layer.
Where Fabric, Databricks and Snowflake Fit
None of the big data platforms is a safety database, and none should replace one. Instead, they work as the governed analytics and AI layer around it. In Kanerika’s view, Microsoft Fabric suits teams already standardized on Power BI and Microsoft 365. In the same view, Databricks fits teams with heavy data engineering and model training needs, while Snowflake fits SQL-centric teams sharing governed data with partners.
The choice matters less than the discipline around it. Shared definitions, access controls and lineage have to exist before any model reads safety data. A broader view of building that base for regulated health data is in the guide to healthcare data strategy .
Watch on YouTube
Business Ontology on Microsoft Fabric: Global Pharma Case Study
A short walkthrough of the governed ontology Kanerika built on Microsoft Fabric for a global pharma enterprise, giving reports and Copilot one shared set of business definitions.
How to Validate AI for Pharmacovigilance
Validation answers one question for one task. Does this tool, used this way, produce output a safety team can rely on? A model that is validated for literature triage is not validated for coding, even when the same vendor supplies both.
Start With Intended Use and an Adjudicated Test Set
Write the intended use first. It should name the task, the input sources, the decision the output supports and the person who acts on it. FDA’s draft guidance also uses the same idea, called the context of use, as the anchor for judging a model’s credibility.
Then build a test set that reflects real inflow, with each case labelled by experienced reviewers who agree on the answer. Include the awkward cases on purpose, such as negations (“no rash reported”), foreign-language reports, multiple products and partial reporter details. Otherwise, a test set without hard cases will flatter any model.
Measure the Errors Safety Teams Care About
Overall accuracy hides the error that matters most. A model that misses one serious event in a hundred can still post a high accuracy score. Track recall on safety content first, then precision, then the cost of reviewing false alarms.
Metric What it measures Safety consequence Owner Event recall Share of true adverse events the tool finds A miss can delay a required report Safety QA Critical-field accuracy Correct reporter, patient, product and event fields Wrong fields flow into submissions Case processing lead Coding acceptance rate Share of MedDRA suggestions accepted unchanged Low rates mean wasted review time Coding lead Unsupported-statement rate Narrative sentences with no source support Invented facts in a regulated record Medical review Duplicate precision Share of flagged pairs that are true duplicates Wrong merges erase real cases Case processing lead Reviewer override rate How often people change the output Very low rates can signal rubber-stamping Safety QA
Each acceptance criterion should be set per task before testing starts, and no universal threshold fits every workflow. Automated checks can help at scale, for example an LLM as a judge that scores narrative drafts for unsupported claims. Those judges need calibration against human reviewers too, as Kanerika’s LLM evaluation framework guide explains.
Release Gates and Revalidation Triggers
Records matter as much as metrics. 21 CFR Part 11 applies to electronic records created or changed under FDA record requirements. FDA’s Part 11 scope guidance narrows some enforcement, but records must still meet the underlying predicate rules. Even so, keep the model suggestion, the reviewer’s edit and the final value together in one audit trail.
Checklist
AI Governance Checklist
A checklist for setting up AI governance across an enterprise, useful when planning validation, human oversight and audit evidence for safety tools.
Get the Checklist → Revalidate when anything that shapes the output changes. That includes a new model version, a prompt or retrieval change, a new intake source and an E2B mapping change. MedDRA is another trigger, because its maintainers release new versions twice a year, in March and September. Safety system vendors list the versions they support, such as MedDRA 29.0 (March 2026) in Oracle Argus Safety 2026.1 .
Failure Modes and the Controls That Catch Them
AI tools in drug safety fail in predictable ways. Knowing the pattern in advance lets a team design the control before the first incident instead of after it.
Hallucinations, Missed Events and False Confidence
Generative models can invent a field that sounds right, such as an onset date the source never gave. Similarly, extraction models can miss an event buried in a long email or misread a negation. In both cases the output looks confident, which is why source links and confidence flags matter more than polish.
A model can also be confidently wrong on a report type it rarely saw in training. Low-confidence routing to people, together with sampling of high-confidence output, catches both kinds of error.
Drift, Reviewer Over-Reliance and Agent Overreach
Drift creeps in when the inflow changes, for example after a product launch or a new patient support programme. Reviewers drift too, though more quietly. When a tool is right on case after case, people start approving without reading, which is the automation bias the EU AI Act warns about.
Agents add one more risk, because they can act across systems. An agent that can gather follow-up items is useful, but one with write access to the safety database is a liability. Kanerika’s guide to agentic AI governance covers least-privilege access, and the post on rogue AI shows how agents go wrong in practice.
Failure mode PV consequence Preventive control Monitoring signal Missed event Late or missing report Recall-first thresholds, sampled QC Events found in QC that the tool missed Invented field False data in a regulated record Source link required for every field Fields without provenance Wrong merge A real case disappears Human merge approval Merge reversals Input drift Accuracy drops when sources change Source-mix monitoring, revalidation Override rate by source Rubber-stamp review Oversight exists on paper only Review time floors, seeded test cases Seeded errors not caught Agent overreach Unreviewed changes to records Read-only access, approval gates Write attempts in access logs Bias or privacy gap Uneven performance, data exposure Subgroup testing, de-identification Error rate by language or region
Watching these signals over time is, in effect, an observability job. Kanerika’s roundup of AI observability tools compares options for tracing model behaviour in production.
How to Measure the ROI of AI in Pharmacovigilance
Model accuracy is not a business case. Value in drug safety means more accepted, compliant output per reviewer hour, with no drop in quality. The numbers below are a method rather than a benchmark.
Build the Baseline and the Full Cost Model
Start with a baseline from your own process. Measure cases per month, minutes per step, rework rates and late reports before any tool goes live. Without that baseline, any claimed saving is a guess.
Then count the full cost. That means licences, cloud usage, integration, validation, sampled QC, retraining and the reviewer time the tool still needs. A useful single measure is quality-adjusted unit cost, that is, total workflow cost divided by accepted, compliant outputs.
Run Conservative, Base and Upside Scenarios
Released capacity equals eligible volume times adoption rate times net minutes saved per case. For example, take a hypothetical team with 20,000 eligible cases a year, 60% adoption and 12 net minutes saved per case. That team then releases 144,000 minutes, or 2,400 reviewer hours, a year.
Run the same sum with lower and higher inputs to get a range rather than one number. Released capacity is time that can go to harder cases rather than an automatic headcount cut. Avoid putting a value on “prevented adverse events”, since no tool can prove that claim.
AI Assessment
How Ready Is Your Team for AI in Safety Operations?
Score your AI maturity across data, governance and operations to see which pharmacovigilance tasks are ready for a pilot and which need groundwork first.
Start Your AI Assessment → A 90-Day Pilot Plan and Maturity Model
The best first project is bounded, measurable and easy to recover from. For instance, intake routing and literature triage both fit that test. Narrative drafting and signal ranking come later, once the data and controls have proven themselves.
Where Is Your Team Today?
Maturity decides how fast a team can move, so place your team on a simple four-stage scale before choosing a pilot.
Manual and fragmented. Reports live in inboxes and spreadsheets, so the first step is to standardize intake and data fields.Standardized and data-ready. Fields, lineage and access controls are consistent, which means one assistive pilot can start.Validated assistance. One or two tools are validated with an audit trail, and the next step is monitoring and revalidation.Governed, scaled automation. Several tools run under risk-tiered oversight, and only then does signal work make sense.Run a Gated Pilot
Set go and no-go criteria before day one, then move through six gates.
Define scope, intended use and the baseline metrics. Secure data access, privacy review and a governed sandbox. Build a prototype and test it on the adjudicated set. Run in shadow mode beside the live process, with no effect on cases. Move to a controlled pilot with full human review and sampled QC. Decide to scale, adjust or stop, based on the criteria set at the start. A pilot that stops at gate five is still a success if it produces evidence. After all, a clear “no” saves a team from building on a tool that would not pass an inspection. Kanerika’s AI strategy consulting helps teams pick and size that first use case.
How Kanerika Helps Safety Teams Put AI to Work
Kanerika works as a data and AI implementation partner. Safety, quality and IT teams keep ownership of the safety system and of every regulatory decision. Kanerika has no published pharmacovigilance case study, so the evidence below comes from adjacent pharma data work and one compliance project outside pharma.
Pharma Data Foundations
AI in safety operations starts with the data underneath it. For a multinational pharmaceutical company, Kanerika designed and deployed a data lake serving 15+ use cases . It ran on a new Hadoop stack with improved data pipelines and self-service dashboards. The client reported a 45% reduction in response times, a 40% increase in data accuracy and a 25% increase in data-driven decisions.
Case Study
45% Faster Response Times with Hadoop Data Platform
For a multinational pharmaceutical company, Kanerika designed and deployed a data lake serving 15+ use cases, with 45% faster response times and 40% higher data accuracy.
Read the Case Study → Shared definitions come next, because AI answers are only as consistent as the terms behind them. For a global pharmaceutical enterprise, Kanerika centralized KPI definitions and business rules in a governed ontology on Microsoft Fabric . It then extended that ontology into Fabric AI and Copilot. The case reports 70% less investigation and reconciliation time, with 85+ KPIs standardized and 40+ entities and relationships modeled.
Adjacent Work: Screening and Documents
Screening is the closest pattern to literature and media monitoring. Outside pharma, Kanerika built an AI compliance agent that screens experts for negative news across public sources against a compliance rulebook. That project reports 3X faster expert vetting and a 70% decrease in backlog cases.
Document work follows the same logic. KlarityIQ , Kanerika’s document intelligence agent, answers questions from company documents, tying each answer to its source data. Teams planning controls can start with Kanerika’s AI governance consulting and its pharma industry work, then scope one workflow for assessment.
So How Should a Safety Team Use AI in Pharmacovigilance?
AI in pharmacovigilance is worth using where volume is high and the output can be checked. In practice, that covers intake, literature screening, coding suggestions, duplicate checks and signal ranking. Validity, seriousness, causality, merges and submission sign-off stay with accountable people.
The safe route is narrow and documented. Pick one bounded task, validate it against an adjudicated test set, keep the audit trail and revalidate when anything changes. Deployed that way, AI clears the noise faster, and safety experts get more time for the signals that matter.
Frequently Asked Questions
How is AI used in pharmacovigilance?
AI in pharmacovigilance supports the high-volume parts of drug safety work. Models classify and extract details from inbound reports, rank literature abstracts, suggest MedDRA terms, flag likely duplicates and help prioritize signals. Generative models can draft case narratives from source documents. Qualified people still confirm validity and seriousness, judge causality and sign off every submission.
What are the benefits of AI in pharmacovigilance?
The main benefit is reviewer time. When AI handles first-pass triage, extraction and coding suggestions, safety experts spend more of their day on medical judgment and signal review. Other gains include more consistent data entry and earlier attention to strong signals. Each benefit should be measured against a baseline from your own process, not assumed.
Can AI replace pharmacovigilance professionals?
No. AI can prepare evidence, but the marketing authorization holder remains accountable for case validity, seriousness, causality and submissions. Regulators and the CIOMS XIV report stress human oversight scaled to risk. In practice, AI changes the work of safety professionals, moving time away from data entry and toward review, investigation and decision-making.
What is the difference between AI and generative AI in pharmacovigilance?
Traditional AI in safety work classifies, extracts and scores, for example finding an adverse event mention or ranking an abstract. Generative AI writes new text, such as a draft case narrative or a translation. Generative output carries a higher risk of unsupported statements, so every sentence needs a traceable source and a reviewer who checks it.
How do you validate AI for pharmacovigilance?
Start by writing the intended use for one task. Build an adjudicated test set from real inflow, including hard cases like negations and foreign-language reports. Measure event recall before precision, set acceptance criteria per task, keep an audit trail of suggestions and edits, and revalidate whenever models, prompts, sources or MedDRA versions change.
Is AI in pharmacovigilance approved by regulators?
There is no blanket regulatory approval for AI in drug safety. FDA’s AI guidance from January 2025 is still a draft, and the FDA-EMA principles and CIOMS XIV report are non-binding. The binding reporting rules, such as 15-day timelines and E2B(R3) formats, apply whether a person or a model processes the case.
What are AI agents in pharmacovigilance?
AI agents are systems that carry out multi-step tasks across tools, such as gathering missing follow-up details or preparing a review queue. They can save time on coordination work. Because they act across systems, they should run with read-only or tightly scoped access, and any change to the safety database should pass a human approval step.
What is the best first AI use case for a pharmacovigilance team?
Pick a task that is bounded, measurable and easy to recover from. Intake routing and literature triage both fit, because errors show up at the next step and output can be checked against the source. Run it in shadow mode first, compare it with your baseline, and decide to scale only on evidence.
When does E2B(R3) become mandatory for FDA postmarketing reports?
FDA states that beginning October 1, 2026, all individual case safety reports submitted through ESG NextGen must use E2B(R3) data standards. FDA accepted E2B(R2) reports through September 30, 2026. Reports sent through the Safety Reporting Portal need no change. AI extraction tools should map output to the R3 fields, including event-level seriousness.
Does the EU AI Act classify pharmacovigilance tools as high-risk?
Not by default. Classification depends on what a system does and the context it runs in. After the AI Omnibus, high-risk rules for Annex III use cases apply from 2 December 2027, and rules for AI inside Annex I regulated products apply from 2 August 2028. Safety teams should assess each tool individually.
